abstract
Non-serous, borderline tumors and
low-grade serous subtypes were excluded.
OBJECTIVE:
High-grade serous carcinoma (HGSC) generally presents at an advanced
stage with poor long-term (LT) survival. Here we describe clinical
features found in women surviving
HGSC for ten or more years.
METHODS:
A
multi-center research consortium was established between five
participating academic centers. Patient selection criteria included
high-grade serous ovarian, fallopian tube, or peritoneal carcinoma with
at least ten years of follow up.
Non-serous, borderline tumors and
low-grade serous subtypes were excluded.
RESULTS:
The
203 identified LT ten-year survivors with HGSC were diagnosed at a
median age of 57years (range 37-84years). The majority of patients had
stage IIIC (72.4%) disease at presentation. Of those who underwent
primary cytoreductive surgery, optimal cytoreduction was achieved in 143
(85.6%) patients. After a median follow up of 144months, 88 (46.8%)
patients did not develop recurrent disease after initial treatment.
Unexpected findings from this survey of LT survivors includes 14% of
patients having had suboptimal cytoreduction, 11% of patients having an
initial platinum free interval of <12months, and nearly 53% of
patients having recurrent disease, yet still surviving more than ten
years after diagnosis.
CONCLUSIONS:
LT
survivors of HGSC of the ovary generally have favorable clinical
features including optimal surgical cytoreduction and primary platinum
sensitive disease. The majority of patients will develop recurrent
disease, however many remained disease free for more than 10years.
Future work will compare the clinical features of this unusual cohort of
LT survivors with the characteristics of HGSC patients having less
favorable outcomes.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.